NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every cell, existing in both oxidized (NAD+) and reduced (NADH) forms. The NAD+/NADH ratio is central to cellular energy metabolism — it is the electron carrier that shuttles electrons through the mitochondrial electron transport chain to produce ATP. Beyond energy production, NAD+ is a required substrate for two classes of longevity-associated enzymes: sirtuins (SIRT1–7: NAD+-dependent deacetylases that regulate gene expression, DNA repair, mitochondrial biogenesis, and metabolic adaptation) and PARPs (PARP1/2: poly-ADP-ribose polymerases that repair DNA strand breaks). Both consume NAD+ during their activity — meaning chronic DNA damage (which increases with age) accelerates NAD+ depletion.
The age-related NAD+ decline is real and well-documented. The question is whether supplementing with NAD+ precursors in humans produces the downstream benefits seen in mice at the doses studied, and whether this translates to meaningful longevity outcomes. The mouse data is compelling and consistent; the human data shows NAD+ levels do rise but functional longevity benefits remain to be established in long-duration trials. This is not a reason to dismiss the field — it is context for calibrating expectations.
| Precursor | Pathway | Human evidence | Cost (monthly) | Considerations |
|---|---|---|---|---|
| NMN (nicotinamide mononucleotide) | Direct NMN → NAD+ via NMNAT (most direct route) | Yoshino 2021 (N=25): 25% muscle NAD+ increase; Igarashi 2022 (N=10): NAD+ rise + metabolic benefits in older men; Liao 2021 (N=80): improved muscle strength and walking speed in older adults | $60–120/month at 500mg/day | Most researched precursor; sublingual form may improve absorption; Sinclair protocol; NMN was briefly removed from FDA supplement market as IND drug (2023 ruling reversed in some jurisdictions — check current status); 500mg–1g/day common research doses |
| NR (nicotinamide riboside) | NR → NMN → NAD+ | Elhassan 2019 (N=12): 90% blood NAD+ increase at 1g/day; Dollerup 2018 (N=40, T2D): NAD+ rise confirmed, no significant metabolic improvement vs placebo; Martens 2018 (N=30, older adults): NAD+ rise, no significant blood pressure effect | $40–80/month at 300mg/day | ChromaDex Tru Niagen is the branded studied form; well-tolerated; no flush; Chromadex holds IP; multiple human trials but most show NAD+ rises without dramatic functional benefits at studied doses and durations |
| Niacin (nicotinic acid) | Niacin → NMN → NAD+ (via Preiss-Handler salvage pathway) | Long-standing cardiovascular data (Coronary Drug Project 1975); Pirinen 2020 (N=40, mitochondrial myopathy): significant NAD+ increase + improved mitochondrial function; niacin raises NAD+ reliably at gram doses | $3–5/month at 500–1000mg/day | Prostaglandin-mediated skin flush is the major tolerability issue (hot/red/itchy skin 30–60 min after dosing); flush reduced by taking with food, aspirin 30 min prior, extended-release forms; most cost-effective precursor; used clinically for decades for lipid management |
| Nicotinamide (NAM) | NAM → NMN → NAD+ (salvage) | Studied for T2D and skin health; raises NAD+ but also inhibits SIRT1 at higher doses (nicotinamide is a product inhibitor of sirtuins) | $5–10/month | Paradoxically, high-dose nicotinamide may inhibit the very sirtuins it's meant to activate; lower doses may avoid this; niacinamide form used topically for skin with strong evidence; avoid as oral longevity protocol due to sirtuin inhibition concern |
Charles Brenner (discoverer of the NR → NAD+ pathway) argues that niacin — available for pennies per dose — raises blood and tissue NAD+ at least as effectively as NMN or NR at practical doses, and that charging $80–120/month for NMN is extracting money from people based on preclinical hype. Brenner's critique is scientifically grounded: the Preiss-Handler pathway (niacin → NAD+) is extremely efficient, and niacin's decades-long safety record is unmatched by any novel precursor. Sinclair counters that the tissue distribution and kinetics of NMN differ from niacin, particularly for brain and muscle NAD+ replenishment, and that resveratrol synergizes with NMN via SIRT1 activation in ways niacin cannot replicate. Both men are correct about parts of the picture. The honest summary: all three precursors raise NAD+; the most cost-effective option with the longest safety record is niacin; NMN has the most targeted research for age-related muscle and metabolic decline; the longevity benefit in humans is unproven for all three.
Cancer cells have high NAD+ demands. Rapidly dividing cancer cells upregulate NAD+ biosynthesis and PARP activity; some oncologists have raised theoretical concerns that NAD+ supplementation could accelerate tumor growth in patients with undiagnosed cancer. This concern is based on mechanistic reasoning, not clinical trial data — there are no human trials showing NAD+ precursors cause or accelerate cancer. PARP inhibitors (which lower NAD+ in cancer cells) are approved cancer treatments. Whether NAD+ supplementation is net beneficial or harmful in cancer contexts is unknown. Individuals with active cancer or high cancer risk should discuss NAD+ supplementation with their oncologist before starting.
Budget option (niacin flush form): Nicotinic acid (niacin) 500mg taken with food; may increase to 500mg twice daily over 2–4 weeks as flush tolerance develops. Take 325mg aspirin 30 minutes prior to reduce prostaglandin-mediated flush. Extended-release niacin reduces flush but carries slightly higher liver enzyme elevation risk (use immediate-release and split doses instead). Cost: ~$3–5/month. Most evidence for cardiovascular benefit at these doses.
No-flush option (NR): Nicotinamide riboside (Tru Niagen or equivalent NR supplement) 300–500mg/day. No flush. Multiple human trials confirming NAD+ elevation. Cost: $40–80/month. Best studied no-flush precursor with the most human trial data.
Muscle/metabolic focus (NMN): NMN 250–500mg/day taken in the morning (Yoshino 2021 used 250mg with significant muscle NAD+ rise). Sublingual NMN may improve absorption. Sinclair protocol adds resveratrol 500mg–1g/day (take with fat for absorption — resveratrol is poorly bioavailable without lipid co-administration) and metformin (prescription). Cost: $60–120/month. Most targeted evidence for skeletal muscle NAD+ and insulin sensitivity.
Synergistic stack: The NAD+ precursor of choice + exercise (exercise independently raises NAD+ via AMPK activation of NAMPT, the rate-limiting enzyme in NAD+ biosynthesis) + caloric restriction or intermittent fasting (activates SIRT1 via NAD+/NADH ratio shift) + adequate sleep (NAD+ recycling occurs during sleep). These behavioral interventions raise NAD+ through independent mechanisms and compound with supplementation. Exercise is the most evidence-supported NAD+-boosting intervention in humans.
As an Amazon Associate, LongevityLab earns from qualifying purchases made through links on this page. This does not affect the price you pay.